Cardiovascular disease is one of the leading causes of death among COPD patients, who have a two to five times higher risk of ischaemic heart disease, cardiac dysrhythmia, and heart failure. For researchers designing trials involving COPD patients, this increased risk means that monitoring the heart is non-negotiable.
In this blog, we will cover:
Cardiac monitoring presents both an opportunity for more accurate data and a necessary safety check. Conditions such as chronic hypoxia, a major symptom of COPD, put persistent stress on the cardiovascular system. As the disease progresses, patients often develop heart strain and pulmonary hypertension, which can elevate a patient’s underlying cardiac risk well before a trial even begins. Patients may have elevated arrhythmia risk and pre-existing cardiovascular conditions that can behave unpredictably when they participate in clinical trials, potentially affecting that study’s results and putting the patients further at risk.
COPD is a difficult disease to monitor, as symptoms can change slowly and flare unpredictably. When these fluctuations overlap with symptoms of COPD therapies, distinguishing drug-related effects from disease progression can be difficult. Furthermore, COPD is heterogenous, so participants in the same trial may exhibit different symptoms and disease patterns, obscuring a trial’s results. Trial therapies have the potential to introduce further complications, as some of the most popular COPD therapies, such as long-acting beta agonists and bronchodilators, are known to have effects on the cardiovascular system, including an elevated heart rate, QT interval changes, and an increased risk of arrhythmias. Altogether, this makes cardiac monitoring a vital data stream for researchers to capture.
While cardiac monitoring is a crucial part of ensuring safety in COPD trials, traditional monitoring methods often fail to capture accurate data. In-clinic ECGs and Holter monitors only offer periodic glimpses of cardiac activity, often missing fluctuations that can signify complications such as transient arrhythmias, which can happen and vanish in minutes. Subtle heart rate variability (HRV) shifts that signal autonomic stress often go undetected between visits. Similarly, drug-related cardiac signals are easily missed by weekly or bi-weekly assessments. This monitoring gap puts both participants and trial outcomes at risk.
Continuous, wearable cardiac monitoring provides a solution. Previous studies have shown that wearable sensors and remote patient monitoring technology can be used to continuously track respiratory rate, HRV, activity levels, and other patient-reported symptoms. These uninterrupted data streams address a key limitation of traditional periodic assessments, catching intermittent patient fluctuations associated with COPD. By capturing the day-to-day experiences of patients in studies, continuous monitoring can provide stronger data for treatment, catching any safety concerns early on in trials.
Beyond supporting data streams, continuous cardiac monitoring is also being examined as a way to create clearer COPD endpoints. Studies show that autonomic dysregulation is another consequence of COPD progression, but emerging COPD therapies demonstrate potential in restoring autonomic balance. This suggests that longitudinal HRV data, which provides non-invasive insights into autonomic function, can be a valuable secondary endpoint in COPD research.
Continuous cardiac monitoring not only closes the data gap introduced by traditional monitoring methods, but it offers a richer, deeper dataset on how certain therapies affect lung function and the broader physiological effects of COPD as well. Medical-grade, wearable ECG technology, such as Vivalink’s ECG patches, are designed to provide that data and ensure automated cloud transmission and full data transparency. For sponsors, this means stronger safety throughout the trial, more complete data, and greater confidence in COPD outcomes.